Maypro announces new patent for Sirtmax black turmeric ingredient for aiding dry eye

Sirtmax is an extract of the rhizome of Kaempferia parviflora, or black turmeric, and its benefits include supporting mitochondrial health by boosting levels of the SIRT1 gene.

Maypro (Purchase, NY) announced that a new U.S. patent has been granted to polymethoxyflavonoid-rich ingredient Sirtmax. Sirtmax was developed by Tokiwa Phytochemical Company, Ltd., (Tokyo) and is exclusively distributed by Maypro in North, South, and Latin America.

Sirtmax is an extract of the rhizome of Kaempferia parviflora, or black turmeric, and its benefits include supporting mitochondrial health by boosting levels of the SIRT1 gene. Now, a new patent demonstrates that Sirtmax can assist people suffering from dry eyes.

“The science behind the new patent demonstrated the clinical efficacy of Sirtmax for increasing tear fluid, an issue of particular interest to elderly and hyperglycemic individuals suffering from dry eye,” the company’s press release states.

According to the company, a double-blind, placebo-controlled human study already showed that Sirtmax helps reduce body weight; maintain blood sugar levels already in a normal range; and decrease production of metabolic waste products, called AGEs; and showed a trend of improving arterial flexibility.